New drug for advanced esophageal cancer after platinum chemo
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment for advanced or returning esophageal squamous cell carcinoma after platinum chemotherapy. It aims to find a better option for people whose cancer has not responded to or has come back after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of esophageal squamous cell carcinoma that is advanced, has returned, or has spread.
- You must have had platinum-based chemotherapy (such as cisplatin or carboplatin) as a first treatment or your cancer returned within 6 months of completing such treatment.
- You must be able to perform daily activities with little to no help (ECOG 0 or 1).
- You must have at least one measurable tumor that can be seen on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs — fruquintinib plus paclitaxel liposome plus nidaplatin — as a first treatment for people with advanced esophageal squamous cell carcinoma that has spread. It aims to see if this combination can help control the cancer better than standard treatments.
This trial tests a new combination of three drugs (fruquintinib, camrelizumab, and capecitabine) for people with colorectal cancer that has spread or cannot be removed and has stopped responding to a standard first chemotherapy. It is for those whose cancer progressed after a specific first treatment called FOLFOXIRI.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial is testing a combination of two oral anti-cancer drugs (fruquintinib and S-1) for people whose metastatic colorectal cancer has not responded to at least two standard treatments. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.